{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:46:30Z","timestamp":1769917590208,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union\u2019s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB"},{"name":"Alzheimer\u2019s Research UK (ARUK) NI Pump Priming","award":["ARUK-2017NC-NI"],"award-info":[{"award-number":["ARUK-2017NC-NI"]}]},{"name":"Alzheimer\u2019s Research UK (ARUK) NI Pump Priming","award":["ARUK-2017NC-NI"],"award-info":[{"award-number":["ARUK-2017NC-NI"]}]},{"name":"Alzheimer\u2019s Research UK (ARUK) NI Pump Priming","award":["ARUK-2017NC-NI"],"award-info":[{"award-number":["ARUK-2017NC-NI"]}]},{"name":"Ulster University Research Challenge Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>\u00a0Dementia is a group of symptoms that largely affects older people. The majority of patients face behavioural and psychological symptoms (BPSD) during the course of their illness. Alzheimer\u2019s disease (AD) and vascular dementia (VaD) are two of the most prevalent types of dementia. Available medications provide symptomatic benefits and provide relief from BPSD and associated health issues. However, it is unclear how specific dementia, antidepressant, antipsychotic, antianxiety, and mood stabiliser drugs, used in the treatment of depression and dementia subtypes are prescribed in hospital admission, during hospital stay, and at the time of discharge. To address this, we apply multi-dimensional data analytical approaches to understand drug prescribing practices within hospitals in England and Wales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We made use of the UK National Audit of Dementia (NAD) dataset and pre-processed the dataset. We evaluated the pairwise Pearson correlation of the dataset and selected key data features which are highly correlated with dementia subtypes. After that, we selected drug prescribing behaviours (e.g. specific medications at the time of admission, during the hospital stay, and upon discharge), drugs and disorders. Then to shed light on the relations across multiple features or dimensions, we carried out multiple regression analyses, considering the number of dementia, antidepressant, antipsychotic, antianxiety, mood stabiliser, and antiepileptic\/anticonvulsant drug prescriptions as dependent variables, and the prescription of other drugs, number of patients with dementia subtypes (AD\/VaD), and depression as independent variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients. During admission, the number of lamotrigine prescriptions was associated with frontotemporal dementia patients, and with the number of valproate and dosulepin prescriptions. During discharge, the number of mirtazapine prescriptions was associated with the number of donepezil prescriptions in conjunction with frontotemporal dementia patients. Finally, the number of prescriptions of donepezil\/memantine at admission, during hospital stay and at discharge exhibited positive association with AD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our analyses reveal a complex, multifaceted set of interactions among prescribed drug types, dementia subtypes, and depression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-022-01892-9","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T12:04:44Z","timestamp":1665144284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals"],"prefix":"10.1186","volume":"22","author":[{"given":"Alok","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula L.","family":"McClean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KongFatt","family":"Wong-Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"1892_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/gps.2193","volume":"24","author":"SFM Bouwens","year":"2009","unstructured":"Bouwens SFM, van Heugten CM, Verhey FRJ. Association between cognition and daily life functioning in dementia subtypes. Int J Geriatr Psychiatry. 2009;24:764\u20139. https:\/\/doi.org\/10.1002\/gps.2193.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1892_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/archneur.58.3.498","volume":"58","author":"D Laurin","year":"2001","unstructured":"Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol. 2001;58:498\u2013504. https:\/\/doi.org\/10.1001\/archneur.58.3.498.","journal-title":"Arch Neurol"},{"key":"1892_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2012.00073","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol MAY. 2012. https:\/\/doi.org\/10.3389\/fneur.2012.00073.","journal-title":"Front Neurol MAY"},{"key":"1892_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12916-014-0192-4","volume":"12","author":"F Bunn","year":"2014","unstructured":"Bunn F, Burn AM, Goodman C, Rait G, Norton S, Robinson L, Schoeman J, Brayne C. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12:192. https:\/\/doi.org\/10.1186\/s12916-014-0192-4.","journal-title":"BMC Med"},{"key":"1892_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.archger.2014.02.010","volume":"59","author":"LA Daiello","year":"2014","unstructured":"Daiello LA, Gardner R, Epstein-Lubow G, Butterfield K, Gravenstein S. Association of dementia with early rehospitalization among Medicare beneficiaries. Arch Gerontol Geriatr. 2014;59:162\u20138. https:\/\/doi.org\/10.1016\/j.archger.2014.02.010.","journal-title":"Arch Gerontol Geriatr"},{"key":"1892_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2016.11.014","author":"BS Diniz","year":"2017","unstructured":"Diniz BS, Teixeira AL, Cao F, Gildengers A, Soares JC, Butters MA, Reynolds CF. History of bipolar disorder and the risk of dementia: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2017. https:\/\/doi.org\/10.1016\/j.jagp.2016.11.014.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1892_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1017\/S1041610211001694","volume":"23","author":"B Draper","year":"2011","unstructured":"Draper B, Karmel R, Gibson D, Peut A, Anderson P. The Hospital dementia services project: age differences in hospital stays for older people with and without dementia. Int Psychogeriatrics. 2011;23:1649\u201358. https:\/\/doi.org\/10.1017\/S1041610211001694.","journal-title":"Int Psychogeriatrics"},{"key":"1892_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.amjopharm.2008.06.004","volume":"6","author":"H Fillit","year":"2008","unstructured":"Fillit H, Nash DT, Rundek T, Zuckerman A. Cardiovascular risk factors and dementia. Am J Geriatr Pharmacother. 2008;6:100\u201318. https:\/\/doi.org\/10.1016\/j.amjopharm.2008.06.004.","journal-title":"Am J Geriatr Pharmacother"},{"key":"1892_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.nurpra.2017.12.032","volume":"14","author":"KS Kverno","year":"2018","unstructured":"Kverno KS, Velez R. Comorbid dementia and depression: the case for integrated care. J Nurse Pract. 2018;14:196\u2013201. https:\/\/doi.org\/10.1016\/j.nurpra.2017.12.032.","journal-title":"J Nurse Pract"},{"key":"1892_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jamda.2007.03.005","volume":"8","author":"JT van der Steen","year":"2007","unstructured":"van der Steen JT, Mehr DR, Kruse RL, Ribbe MW, van der Wal G. Dementia, lower respiratory tract infection, and long-term mortality. J Am Med Dir Assoc. 2007;8:396\u2013403. https:\/\/doi.org\/10.1016\/j.jamda.2007.03.005.","journal-title":"J Am Med Dir Assoc"},{"key":"1892_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jalz.2013.12.018","volume":"11","author":"CW Zhu","year":"2015","unstructured":"Zhu CW, Scarmeas N, Ornstein K, Albert M, Brandt J, Blacker D, Sano M, Stern Y. Health-care use and cost in dementia caregivers: longitudinal results from the Predictors Caregiver Study. Alzheimer\u2019s Dement. 2015;11:444\u201354. https:\/\/doi.org\/10.1016\/j.jalz.2013.12.018.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1892_CR12","unstructured":"NICE. National Institute for Health and Clinical Excellence.Dementia. Guideline on Supporting People With Dementia and Their Carers in Health and Social Care. 2018. https:\/\/www.nice.org.uk\/guidance\/ng97"},{"key":"1892_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-122140","volume":"35","author":"SG Di Santo","year":"2013","unstructured":"Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2013;35:349\u201361. https:\/\/doi.org\/10.3233\/JAD-122140.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1892_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610209990354","author":"J Rodda","year":"2009","unstructured":"Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatrics. 2009. https:\/\/doi.org\/10.1017\/S1041610209990354.","journal-title":"Int Psychogeriatrics"},{"key":"1892_CR15","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199710030-00007","author":"HM Bryson","year":"1997","unstructured":"Bryson HM, Benfield P. Donepezil. Drugs Aging. 1997. https:\/\/doi.org\/10.2165\/00002512-199710030-00007.","journal-title":"Drugs Aging"},{"key":"1892_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00019-2","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data. Neuropharmacology. 1999. https:\/\/doi.org\/10.1016\/S0028-3908(99)00019-2.","journal-title":"Neuropharmacology"},{"key":"1892_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119\u201336. https:\/\/doi.org\/10.1002\/wps.20204.","journal-title":"World Psychiatry"},{"issue":"7771","key":"1892_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/d41586-019-02480-0","volume":"572","author":"D Draaisma","year":"2019","unstructured":"Draaisma D. Lithium: the gripping history of a psychiatric success story. Nature. 2019;572(7771):584\u20135. https:\/\/doi.org\/10.1038\/d41586-019-02480-0.","journal-title":"Nature"},{"key":"1892_CR19","doi-asserted-by":"crossref","unstructured":"Grunze HCR. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin. Neurosci. (2008)","DOI":"10.31887\/DCNS.2008.10.1\/hcrgrunze"},{"key":"1892_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1576\/toag.9.1.009.27290","volume":"9","author":"N Munjuluri","year":"2007","unstructured":"Munjuluri N, Wong W, Yoong W. Anticholinergic drugs for overactive bladder: a review of the literature and practical guide. Obstet Gynaecol. 2007;9:9\u201314. https:\/\/doi.org\/10.1576\/toag.9.1.009.27290.","journal-title":"Obstet Gynaecol"},{"key":"1892_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2020.1830028","author":"AJ McMichael","year":"2020","unstructured":"McMichael AJ, Zafeiridi E, Ryan M, Cunningham EL, Passmore AP, McGuinness B. Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging Ment Health. 2020. https:\/\/doi.org\/10.1080\/13607863.2020.1830028.","journal-title":"Aging Ment Health"},{"key":"1892_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bcp.12617","volume":"80","author":"K Ruxton","year":"2015","unstructured":"Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80:209\u201320. https:\/\/doi.org\/10.1111\/bcp.12617.","journal-title":"Br J Clin Pharmacol"},{"key":"1892_CR23","doi-asserted-by":"publisher","unstructured":"Kachru N, Carnahan RM, Johnson ML, Aparasu RR. Potentially inappropriate anticholinergic medication use in older adults with dementia, In: Journal of the American Pharmacists Association. American Pharmacists Association, 2015. p. 603\u2013612. https:\/\/doi.org\/10.1331\/JAPhA.2015.14288","DOI":"10.1331\/JAPhA.2015.14288"},{"key":"1892_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/CIA.S58830","volume":"9","author":"J Zhang","year":"2014","unstructured":"Zhang J, Liu X, Sun D, Fan Y, Zhou H, Fu B. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Clin Interv Aging. 2014;9:411. https:\/\/doi.org\/10.2147\/CIA.S58830.","journal-title":"Clin Interv Aging"},{"key":"1892_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108118","author":"A Joshi","year":"2020","unstructured":"Joshi A, Wang DH, Watterson S, McClean PL, Behera CK, Sharp T, Wong-Lin KF. Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer\u2019s disease. Neuropharmacology. 2020. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108118.","journal-title":"Neuropharmacology"},{"key":"1892_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/WAD.0000000000000103","volume":"30","author":"C Wang","year":"2016","unstructured":"Wang C, Gao S, Hendrie HC, Kesterson J, Campbell NL, Shekhar A, Callahan CM. Antidepressant use in the elderly is associated with an increased risk of dementia. Alzheimer Dis Assoc Disord. 2016;30:99\u2013104. https:\/\/doi.org\/10.1097\/WAD.0000000000000103.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1892_CR27","first-page":"E488","volume":"64","author":"N Drummond","year":"2018","unstructured":"Drummond N, McCleary L, Freiheit E, Molnar F, Dalziel W, Cohen C, Turner D, Miyagishima R, Silvius J. Antidepressant and antipsychotic prescribing in primary care for people with dementia. Can Fam Physician. 2018;64:E488\u201397.","journal-title":"Can Fam Physician"},{"key":"1892_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1192\/bjp.bp.111.107631","volume":"201","author":"TRE Barnes","year":"2012","unstructured":"Barnes TRE, Banerjee S, Collins N, Treloar A, McIntyre SM, Paton C. Antipsychotics in dementia: Prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry. 2012;201:221\u20136. https:\/\/doi.org\/10.1192\/bjp.bp.111.107631.","journal-title":"Br J Psychiatry"},{"key":"1892_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316658463","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016. https:\/\/doi.org\/10.1177\/2040622316658463.","journal-title":"Ther Adv Chronic Dis"},{"key":"1892_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191\u2013210. https:\/\/doi.org\/10.1097\/01.JGP.0000200589.01396.6d.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1892_CR31","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S2468-2667(17)30031-2","volume":"2","author":"K Donegan","year":"2017","unstructured":"Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Heal. 2017;2:e149\u201356. https:\/\/doi.org\/10.1016\/S2468-2667(17)30031-2.","journal-title":"Lancet Public Heal"},{"key":"1892_CR32","unstructured":"Data table (England and Wales) [WWW Document], 2020. . rcpsych.ac.uk. URL https:\/\/www.rcpsych.ac.uk\/improving-care\/ccqi\/national-clinical-audits\/national-audit-of-dementia\/nad-reports-and-resources\/data-tables#faq-accoridon-collapse2563078b-adf0-4aa7-83ae-b771666af179 (accessed 10.29.20)."},{"key":"1892_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-00296-0_5","volume-title":"Pearson correlation coefficient","author":"J Benesty","year":"2009","unstructured":"Benesty J, Chen J, Huang Y, Cohen I. Pearson correlation coefficient. Berlin, Heidelberg: Springer; 2009. p. 1\u20134. https:\/\/doi.org\/10.1007\/978-3-642-00296-0_5."},{"key":"1892_CR34","doi-asserted-by":"publisher","unstructured":"Aiken LS, West SG, Pitts SC, Baraldi AN, Wurpts IC. Multiple linear regression. In: Handbook of psychology, Second Edition. John Wiley & Sons, Inc., Hoboken, NJ, USA. 2012. https:\/\/doi.org\/10.1002\/9781118133880.hop202018","DOI":"10.1002\/9781118133880.hop202018"},{"key":"1892_CR35","unstructured":"MATLAB. (R2020a), Natick, Massachusetts: The MathWorks Inc, 2020."},{"key":"1892_CR36","doi-asserted-by":"publisher","unstructured":"Bedre. reneshbedre\/bioinfokit: Bioinformatics data analysis and visualization toolkit (Version v0.9) [WWW Document]. 2020. https:\/\/doi.org\/10.5281\/zenodo.3965241","DOI":"10.5281\/zenodo.3965241"},{"key":"1892_CR37","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients. Anesth Analg. 2018;126:1763\u20138. https:\/\/doi.org\/10.1213\/ANE.0000000000002864.","journal-title":"Anesth Analg"},{"key":"1892_CR38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2147\/NDT.S163842","volume":"14","author":"J Masopust","year":"2018","unstructured":"Masopust J, Protopopov\u00e1 D, Vali\u0161 M, Pavelek Z, Kl\u00edmov\u00e1 B. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. Neuropsychiatr Dis Treat. 2018;14:1211\u201320. https:\/\/doi.org\/10.2147\/NDT.S163842.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1892_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.9740\/mhc.n204508","volume":"4","author":"WM Buterbaugh","year":"2014","unstructured":"Buterbaugh WM, Jamrose T, Lazzara J, Honaker L, Thomas CJ. Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD). Ment Heal Clin. 2014;4:183\u20138. https:\/\/doi.org\/10.9740\/mhc.n204508.","journal-title":"Ment Heal Clin"},{"key":"1892_CR40","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.1016\/j.jagp.2019.01.097","volume":"27","author":"K Kanaya","year":"2019","unstructured":"Kanaya K, Hanyu H. Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer\u2019s disease\u2014study of changes in cerebral blood flow by spect imaging-. Am J Geriatr Psychiatry. 2019;27:S183\u20134. https:\/\/doi.org\/10.1016\/j.jagp.2019.01.097.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1892_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1345\/aph.1K372","volume":"42","author":"ID Maidment","year":"2008","unstructured":"Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42:32\u20138. https:\/\/doi.org\/10.1345\/aph.1K372.","journal-title":"Ann Pharmacother"},{"key":"1892_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00002826-200211000-00007","volume":"25","author":"D Paleacu","year":"2002","unstructured":"Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer\u2019s disease. Clin Neuropharmacol. 2002;25:313\u20137. https:\/\/doi.org\/10.1097\/00002826-200211000-00007.","journal-title":"Clin Neuropharmacol"},{"key":"1892_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/cia.s1698","volume":"2","author":"E Hersch","year":"2008","unstructured":"Hersch E. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2008;2:611\u201321. https:\/\/doi.org\/10.2147\/cia.s1698.","journal-title":"Clin Interv Aging"},{"key":"1892_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01168","author":"R Magierski","year":"2020","unstructured":"Magierski R, Sobow T, Schwertner E, Religa D. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.01168.","journal-title":"Front Pharmacol"},{"key":"1892_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s13670-019-0269-1","author":"CL McDermott","year":"2019","unstructured":"McDermott CL, Gruenewald DA. Pharmacologic management of agitation in patients with dementia. Curr Geriatr Rep. 2019. https:\/\/doi.org\/10.1007\/s13670-019-0269-1.","journal-title":"Curr Geriatr Rep"},{"key":"1892_CR46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jppr.1403","volume":"48","author":"A Page","year":"2018","unstructured":"Page A, Etherton-Beer C, Seubert LJ, Clark V, Hill X, King S, Clifford RM. Medication use to manage comorbidities for people with dementia: a systematic review. J Pharm Pract Res. 2018;48:356\u201367. https:\/\/doi.org\/10.1002\/jppr.1403.","journal-title":"J Pharm Pract Res"},{"key":"1892_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1570159x14666151208114232","volume":"14","author":"F Wang","year":"2016","unstructured":"Wang F, Feng T-Y, Yang S, Preter M, Zhou J-N, Wang X-P. Drug Therapy for behavioral and psychological symptoms of dementia. Curr Neuropharmacol. 2016;14:307\u201313. https:\/\/doi.org\/10.2174\/1570159x14666151208114232.","journal-title":"Curr Neuropharmacol"},{"key":"1892_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fphar.2015.00116","volume":"6","author":"TJ Anastasio","year":"2015","unstructured":"Anastasio TJ. Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease. Front Pharmacol. 2015;6:116. https:\/\/doi.org\/10.3389\/fphar.2015.00116.","journal-title":"Front Pharmacol"},{"key":"1892_CR49","doi-asserted-by":"publisher","DOI":"10.4103\/0976-7800.191021","author":"H Gujjarlamudi","year":"2016","unstructured":"Gujjarlamudi H. Polytherapy and drug interactions in elderly. J Midlife Health. 2016. https:\/\/doi.org\/10.4103\/0976-7800.191021.","journal-title":"J Midlife Health"},{"key":"1892_CR50","unstructured":"Cloak N, Khalili Y Al. Behavioral and psychological symptoms in dementia. StatPearls Publishing LLC: Treasure Island, FL, USA; 2020."},{"key":"1892_CR51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12916-020-01841-1","volume":"18","author":"K Wong-Lin","year":"2020","unstructured":"Wong-Lin K, McClean PL, McCombe N, Kaur D, Sanchez-Bornot JM, Gillespie P, Todd S, Finn DP, Joshi A, Kane J, McGuinness B. Shaping a data-driven era in dementia care pathway through computational neurology approaches. BMC Med. 2020;18:398. https:\/\/doi.org\/10.1186\/s12916-020-01841-1.","journal-title":"BMC Med"},{"key":"1892_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","volume":"18","author":"PB Rosenberg","year":"2010","unstructured":"Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136\u201345. https:\/\/doi.org\/10.1097\/JGP.0b013e3181c796eb.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1892_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2125.2004.01801.x","volume":"58","author":"CF Nagy","year":"2004","unstructured":"Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multipe oral doses. Br J Clin Pharmacol Suppl. 2004;58:25\u201333. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.01801.x.","journal-title":"Br J Clin Pharmacol Suppl"},{"issue":"Suppl 1","key":"1892_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/00003088-199700321-00007","volume":"32","author":"MJ Gardner","year":"1997","unstructured":"Gardner MJ, Baris BA, Wilner KD, Preskorn SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet. 1997;32(Suppl 1):43\u20139. https:\/\/doi.org\/10.2165\/00003088-199700321-00007 (PMID: 9068935).","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1892_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/00002512-200219050-00006","volume":"19","author":"RB Muijsers","year":"2002","unstructured":"Muijsers RB, Plosker GL, Noble S. Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging. 2002;19(5):377\u201392. https:\/\/doi.org\/10.2165\/00002512-200219050-00006 (PMID: 12093324).","journal-title":"Drugs Aging"},{"issue":"10","key":"1892_CR56","doi-asserted-by":"publisher","first-page":"pyv055","DOI":"10.1093\/ijnp\/pyv055","volume":"18","author":"M Defrancesco","year":"2015","unstructured":"Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of benzodiazepines in Alzheimer\u2019s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pyv055. https:\/\/doi.org\/10.1093\/ijnp\/pyv055.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1892_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0379-0738(01)00632-6","volume":"126","author":"B Jonasson","year":"2002","unstructured":"Jonasson B, Saldeen T. Citalopram in fatal poisoning cases. Forensic Sci Int. 2002;126(1):1\u20136. https:\/\/doi.org\/10.1016\/s0379-0738(01)00632-6 (PMID: 11955823).","journal-title":"Forensic Sci Int"},{"key":"1892_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1745-0179-3-3","volume":"3","author":"M Pasquini","year":"2007","unstructured":"Pasquini M, Picardi A, Speca A, Orlandi V, Tarsitani L, Morosini P, Cascavilla I, Biondi M. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: an open study. Clin Pract Epidemiol Mental Health CP EMH. 2007;3:3. https:\/\/doi.org\/10.1186\/1745-0179-3-3.","journal-title":"Clin Pract Epidemiol Mental Health CP EMH"},{"issue":"1","key":"1892_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40501-017-0102-4","volume":"4","author":"EA Crocco","year":"2017","unstructured":"Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological management of anxiety disorders in the elderly. Curr Treat Opt Psychiatry. 2017;4(1):33\u201346. https:\/\/doi.org\/10.1007\/s40501-017-0102-4.","journal-title":"Curr Treat Opt Psychiatry"},{"issue":"3","key":"1892_CR60","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/YIC.0b013e3282f424c2","volume":"23","author":"AJ Lenox-Smith","year":"2008","unstructured":"Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008;23(3):113\u20139. https:\/\/doi.org\/10.1097\/YIC.0b013e3282f424c2 (PMID: 18408525).","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"1892_CR61","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3892\/etm.2012.869","volume":"5","author":"J Zhang","year":"2013","unstructured":"Zhang J, Xu H, Chen Z. Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder. Exp Ther Med. 2013;5(3):840\u20134. https:\/\/doi.org\/10.3892\/etm.2012.869.","journal-title":"Exp Ther Med"},{"key":"1892_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00596","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML. The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00596.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1892_CR63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.eurpsy.2007.03.001","volume":"22","author":"M Rainer","year":"2007","unstructured":"Rainer M, Haushofer M, Pfolz H, Struhal C, Wick W. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry. 2007;22(6):395\u2013403. https:\/\/doi.org\/10.1016\/j.eurpsy.2007.03.001 (Epub 2007 May 4 PMID: 17482432).","journal-title":"Eur Psychiatry"},{"key":"1892_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183586","volume":"12","author":"R Chen","year":"2017","unstructured":"Chen R, Chan P-T, Chu H, Lin Y-C, Chang P-C, Chen C-Y, Chou K-R. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. PLoS ONE. 2017;12: e0183586. https:\/\/doi.org\/10.1371\/journal.pone.0183586.","journal-title":"PLoS ONE"},{"key":"1892_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/ebmh.7.3.76","author":"RH McShane","year":"2004","unstructured":"McShane RH. Memantine plus donepezil improves physical and mental health in people with Alzheimer\u2019s disease: Commentary. Evid Based Ment Health. 2004. https:\/\/doi.org\/10.1136\/ebmh.7.3.76.","journal-title":"Evid Based Ment Health"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-022-01892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-022-01892-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-022-01892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T12:04:59Z","timestamp":1665144299000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-022-01892-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1186\/s12911-022-01892-9","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required in this analytical work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}